Alivus Life Sciences: The financial results for the period ended September 30, 2026
Alivus Life Sciences (ALIVUS) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹17,152 crore.
What happened
Alivus Life Sciences (ALIVUS) filed a disclosure with the exchanges on 29 October 2026 at 07:21 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Alivus Life Sciences is a small-cap company in the Healthcare sector, with a market value of about ₹17,152 crore.
The stock last traded at ₹1,397.4, against a 52-week range of ₹819–₹1,493.8 (6.5% below the high).
Before this filing the shares had moved +2.5% over the month and +25.0% over three months. Average daily turnover over the last 20 sessions was about ₹14.07 crore.
Promoters held 74.87% at the end of Q1 FY27. Foreign institutions owned 5.54% and domestic institutions 7.18%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 602 | 121.5 | 9.91 |
| Q2 FY26 | 588 | 130 | 10.6 |
| Q3 FY26 | 673 | 150.3 | 12.25 |
| Q4 FY26 | 689 | 162.7 | 13.23 |
| Q1 FY27 | 640 | 160.1 | 13.04 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.6% over five days; 55% of them rose the next day.
Market-wide, 10,043 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 29 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.